Megatrends from the 2019 Deloitte Life Sciences Outlook
Investing in Canadian Health: We Know the Cost, but Can We Talk About Value?
Year in Review – Transformational Transactions Dominated 2018
Egypt’s Fake Drug Problem
Egypt to Establish the “Egyptian Drug Authority”
Korea to Strengthen Support for Rare Disease Patients
Canada: Targeting Rare Diseases
People You Should Know in Canadian Pharma
AstraZeneca’s EUR 135 Million Investment in France
Egypt’s Hep C ‘Tour n’ Cure’ – Friend or Foe?
Egypt: Tackling Hep C
Korean Healthcare and Pharma’s 10-Year Plan
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here